JP2024529430A5 - - Google Patents
Info
- Publication number
- JP2024529430A5 JP2024529430A5 JP2024504503A JP2024504503A JP2024529430A5 JP 2024529430 A5 JP2024529430 A5 JP 2024529430A5 JP 2024504503 A JP2024504503 A JP 2024504503A JP 2024504503 A JP2024504503 A JP 2024504503A JP 2024529430 A5 JP2024529430 A5 JP 2024529430A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition according
- week
- period
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163225707P | 2021-07-26 | 2021-07-26 | |
| US63/225,707 | 2021-07-26 | ||
| US202163285327P | 2021-12-02 | 2021-12-02 | |
| US63/285,327 | 2021-12-02 | ||
| PCT/US2022/038188 WO2023009438A1 (en) | 2021-07-26 | 2022-07-25 | 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024529430A JP2024529430A (ja) | 2024-08-06 |
| JP2024529430A5 true JP2024529430A5 (https=) | 2025-07-24 |
Family
ID=82932627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024504503A Pending JP2024529430A (ja) | 2021-07-26 | 2022-07-25 | がんの処置における使用のための１－（４－｛［４－（ジメチルアミノ）ピペリジン－１－イル］カルボニル｝フェニル）－３－［４－（４，６－ジモルホリン－４－イル－１，３，５－トリアジン－２－イル）フェニル］尿素（ゲダトリシブ）およびその組合せ |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12350276B2 (https=) |
| EP (1) | EP4376848A1 (https=) |
| JP (1) | JP2024529430A (https=) |
| KR (1) | KR20240040768A (https=) |
| AU (2) | AU2022320615B2 (https=) |
| CA (1) | CA3227191A1 (https=) |
| CL (1) | CL2024000208A1 (https=) |
| IL (1) | IL310243A (https=) |
| MX (1) | MX2024001266A (https=) |
| TW (1) | TW202320795A (https=) |
| WO (1) | WO2023009438A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025049962A1 (en) * | 2023-08-31 | 2025-03-06 | Aadi Bioscience, Inc. | Combination cancer treatments with a composition comprising an mtor pathway inhibitor |
| US20260053814A1 (en) * | 2024-08-21 | 2026-02-26 | Celcuity Inc. | Treatment regimens for gedatolisib in hormonally-driven disorders |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5998402A (en) | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| MXPA04005939A (es) | 2002-01-22 | 2005-01-25 | Warner Lambert Co | 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas. |
| GB0327380D0 (en) | 2003-11-25 | 2003-12-31 | Cyclacel Ltd | Method |
| EP1846408B1 (en) | 2005-01-14 | 2013-03-20 | Janssen Pharmaceutica NV | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
| LT2294072T (lt) | 2008-05-23 | 2017-06-12 | Wyeth Llc | Triazino junginiai, kaip p13 kinazės ir mtor inhibitoriai |
| US10022381B2 (en) | 2008-05-23 | 2018-07-17 | Pfizer Inc. | Triazine compounds as PI3 kinase and mTOR inhibitors |
| ES2522346T3 (es) | 2008-08-22 | 2014-11-14 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de CDK |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| MX338327B (es) | 2010-10-25 | 2016-04-12 | G1 Therapeutics Inc | Inhibidores de cdk. |
| WO2013090829A1 (en) | 2011-12-14 | 2013-06-20 | Aragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| CA2868966C (en) | 2012-03-29 | 2021-01-26 | Francis Xavier Tavares | Lactam kinase inhibitors |
| CA2915534A1 (en) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Azetidine estrogen receptor modulators and uses thereof |
| PE20170312A1 (es) | 2014-03-14 | 2017-03-30 | Pfizer | Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso |
| ES2881214T3 (es) | 2014-12-17 | 2021-11-29 | Pfizer | Formulaciones de un inhibidor de PI3K/mTOR para la administración intravenosa |
| SI3672571T1 (sl) | 2017-08-25 | 2022-01-31 | Pfizer Inc. | Farmacevtska vodna raztopina, ki vsebuje 1-(4-((4-(dimetilamino) piperdin-1-il)karbonil)fenil)-3-(4-(4,6-dimorfolin-4-il-1,3, 5-triazin-2-il)fenil)sečnino |
| EP4249069B1 (en) | 2018-06-07 | 2025-11-19 | Pfizer Inc. | Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea |
| EP3863618A1 (en) * | 2018-10-08 | 2021-08-18 | F. Hoffmann-La Roche AG | Methods of treating cancer with pi3k alpha inhibitors and metformin |
-
2022
- 2022-07-25 CA CA3227191A patent/CA3227191A1/en active Pending
- 2022-07-25 EP EP22754997.9A patent/EP4376848A1/en active Pending
- 2022-07-25 US US17/872,721 patent/US12350276B2/en active Active
- 2022-07-25 IL IL310243A patent/IL310243A/en unknown
- 2022-07-25 AU AU2022320615A patent/AU2022320615B2/en active Active
- 2022-07-25 MX MX2024001266A patent/MX2024001266A/es unknown
- 2022-07-25 TW TW111127690A patent/TW202320795A/zh unknown
- 2022-07-25 WO PCT/US2022/038188 patent/WO2023009438A1/en not_active Ceased
- 2022-07-25 KR KR1020247005862A patent/KR20240040768A/ko active Pending
- 2022-07-25 JP JP2024504503A patent/JP2024529430A/ja active Pending
-
2024
- 2024-01-24 CL CL2024000208A patent/CL2024000208A1/es unknown
-
2025
- 2025-06-05 US US19/229,722 patent/US20250345342A1/en active Pending
- 2025-08-27 AU AU2025223785A patent/AU2025223785A1/en active Pending